Crinetics Pharmaceuticals ( (CRNX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Crinetics Pharmaceuticals has seen its stock price rise following the initiation of a Phase 1/2 study for its candidate CRN09682, aimed at targeting specific tumors. Additionally, the company’s price target has been raised due to strategic initiatives and promising growth prospects, including a successful earnings call that highlighted their PALSONIFY product. This reflects increased confidence in their market entry and financial position.
More about Crinetics Pharmaceuticals
YTD Price Performance: -12.22%
Average Trading Volume: 1,642,879
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.29B
For further insights into CRNX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.